FIELD: organic chemistry, medicine, endocrinology, pharmacy.
SUBSTANCE: invention relates to S-enantiomers of compound of the formula (I): 
wherein n means a number 1 or 2. S-enantiomers of compound of the formula (I) are chosen from (2S)-3-(4-{2-[benzyl(hexyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypropionic acid and (2S)-2-ethoxy-3-(4-{2-[hexyl-(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propionic acid and their pharmaceutically acceptable salts and solvates. Also, invention relates to a pharmaceutical preparation possessing agonistic activity with respect to PPARα (human alpha-receptors activated by peroxisome proliferator) and comprising compound of the formula (I) in mixture with pharmaceutically acceptable adjuvants, excipients and/or carriers. S-enantiomer of the formula (I) is used in producing a medicinal agent used in treatment of lipid disorders (dyslipidemia) associated with or not associated with resistance to insulin. Also, this compound is used in treatment or prophylaxis of lipid disorders (dyslipidemia) associated or not associated with resistance to insulin and diabetes mellitus type 2. Invention provides using derivatives of phenylpropionic acid as agonists of human alpha-receptors activated by peroxisome proliferator (PPARα).
EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.
12 cl, 3 ex
